General Information of Drug (ID: DMROSHN)

Drug Name
Velneperit Drug Info
Synonyms
Velneperit; 342577-38-2; S-2367; UNII-09BQ2KJ22J; 09BQ2KJ22J; Velneperit [USAN:INN]; Velneperit (USAN/INN); SCHEMBL2806595; SCHEMBL13204979; SCHEMBL10114559; CHEMBL2016681; SCHEMBL10134095; BCP16623; BDBM50380914; AKOS027338754; ZINC257354192; DB12889; CS-5388; KB-81432; HY-14423; BC282913; D08026; 577V382; S-2367;S2367;S 2367; trans-4-(((1,1-Dimethylethyl)sulfonyl)amino)-N-(5-(trifluoromethyl)pyridin-2-yl)cyclohexanecarboxamide; Cyclohexanecarboxamide, 4-(((1,1-dimethylethyl)sulfonyl)amino)-N-(5-(trifluoromethyl)-2-pyridinyl)-, tr
Indication
Disease Entry ICD 11 Status REF
Obesity 5B81 Discontinued in Phase 2 [1]
Cross-matching ID
PubChem CID
20629114
CAS Number
CAS 342577-38-2
TTD Drug ID
DMROSHN

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Discontinued Drug(s)
Preclinical Drug(s)
Investigative Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
CGP71683A DMRYC08 Obesity 5B81 Discontinued in Phase 3 [3]
S-234462 DM80P4U Obesity 5B81 Discontinued in Phase 1 [2]
Axovan-3 DM1JN6A Eating disorder 6B82 Discontinued in Phase 1 [4]
FR-79620 DMXR287 Diabetic complication 5A2Y Preclinical [5]
GW-594884A DMHUD27 Obesity 5B81 Preclinical [5]
NPY5RA-972 DMXUCSN Obesity 5B81 Preclinical [5]
RWJ-49815 DMUGZMO Fungal infection 1F29-1F2F Terminated [4]
AR-129330 DMUSYKG Discovery agent N.A. Investigative [6]
Bis(31/31')[[Cys(31), Nva(34)]NPY(27-36)-NH(2)] DMKANOH Discovery agent N.A. Investigative [7]
S-25585 DMBUD1M Eating disorder 6B82 Investigative [4]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Neuropeptide Y receptor type 5 (NPY5R) TTY6EWA NPY5R_HUMAN Antagonist [2]

References

1 New and emerging drug molecules against obesity. J Cardiovasc Pharmacol Ther. 2014 Jan;19(1):65-76.
2 Clinical pipeline report, company report or official report of Shionogi (2011).
3 Neuropeptide Y-induced enhancement of the evoked release of newly synthesized dopamine in rat striatum: mediation by Y2 receptors. Neuropharmacology. 2007 May;52(6):1396-402.
4 Emerging drugs for eating disorder treatment. Expert Opin Emerg Drugs. 2006 May;11(2):315-36.
5 Emerging drugs for obesity: linking novel biological mechanisms to pharmaceutical pipelines. Expert Opin Emerg Drugs. 2005 Aug;10(3):643-60.
6 Lead optimization of 4-(dimethylamino)quinazolines, potent and selective antagonists for the melanin-concentrating hormone receptor 1. Bioorg Med Chem Lett. 2005 Sep 1;15(17):3853-6.
7 Bis(31/31')[[Cys(31), Nva(34)]NPY(27-36)-NH(2)]: a neuropeptide Y (NPY) Y(5) receptor selective agonist with a latent stimulatory effect on food intake in rats. Peptides. 2002 Aug;23(8):1485-90.